The ETF received a Zacks ETF Rank of 2 (Buy), has strong year-to-date performance of 20.18%, competitive expense ratio of 0.37%, and offers effective diversification with 63 holdings and medium risk profile suitable for long-term investors.
Articles that tag IHF but are mainly about other companies.
Lower drug prices reduce insurers' pharmacy costs, potentially improving medical-loss ratios. Mixed-to-moderately positive impact expected as healthcare providers benefit from cost savings.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology